Time needed to heal TalkMed's wound from CEO Ang's suspension: RHB

-A +A

SINGAPORE (April 27): RHB is maintaining its “Neutral” call on TalkMed Group with a lower target price of 70 cents, from 72 cents previously, after the group reported a weak 1Q18 set of financial results.  

To recap, the private healthcare services group saw its topline fall 25.7% on-year due to the eight-month suspension of its key revenue contributor and CEO, Ang Peng Tiam, who only resumed his medical duties last month on March 25. 

In a Friday report, lead analyst Jarick Seet said he sees better quarters ahead for TalkMed with Ang’s return to the medical practice, although he thinks it would take...(click on link for full story on theedgesingapore.com)